Organogenesis reports Q1 EPS (17c), consensus (3c)

Reports Q1 revenue $86.69M, consensus $90.77M. “I’m proud of the team’s continued dedication to our customers and their patients in this challenging market. We managed the anticipated disruption well and I’m confident in our ability to execute on our commercial strategy for the remainder of the year,” said Gary Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis (ORGO). “With our strong brand equity, diverse portfolio and deep customer relationships, we remain well-positioned to navigate the evolving reimbursement landscape.”